Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of .

Neuroblastoma breakpoint family, member 1 (), appears to be a double-edged sword with regard to its role in carcinogenesis. On the one hand, the tumor-suppressing functions of have been definitively observed in neuroblastoma, prostate cancer, cutaneous squamous cell carcinoma, and cervical cancer. On the other hand, there is evidence that regulates the colony formation, invasion, and maintenance of liver cancer cells and hence functions as an oncogene. The roles of are strictly dependent on the biological context and type of organization. However, a systematic pan-cancer analysis has thus far not been undertaken, and the significance of in the occurrence and progression of many malignancies is uncertain. In this paper, bioinformatics techniques were employed to analyze expression across different cancers and investigate the relationship between and clinical features, prognosis, genetic alteration, and tumor immune microenvironment, respectively. Our results show that is variably expressed in distinct tumor tissues and is also closely linked to clinical outcomes. In particular, compared to other tumor types, there was a strong negative correlation between expression and various components of the tumor microenvironment in adrenocortical carcinoma (ACC). We thus developed an -derived immune risk model based on -related immune genes; ACC patients with a high-risk score tended to have a poorer prognosis, accompanied by immune hyporesponsiveness. can be used as a prognostic biomarker for multiple cancers. Moreover, anti- immunotherapy may be suitable for treating ACC patients.